In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states

Antonio L. Velez Perez, Suzannah M. Schmidt-Malan, Peggy C. Kohner, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Robin Patel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pseudomonas aeruginosa causes a variety of life-threatening infections, some of which are associated with planktonic and others with biofilm states. Herein, we tested the combination of the novel cephalosporin, ceftolozane, with the β-lactamase inhibitor, tazobactam, against planktonic and biofilm forms of 54 clinical isolates of P. aeruginosa, using cefepime as a comparator. MIC values were determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum biofilm inhibitory concentration (MBIC) values were determined using biofilm-laden pegged lids incubated in antimicrobial challenge plates containing varying concentrations of ceftolozane/tazobactam. Pegged lids were then incubated in growth recovery plates containing cation-adjusted Mueller-Hinton broth to determine the minimum biofilm bactericidal concentration (MBBC). Ceftolozane/tazobactam was highly active against planktonic P. aeruginosa, with all 54 isolates studied testing susceptible (MIC ≤4/4μg/mL). On the other hand, 51/54 biofilm P. aeruginosa had MBICs ≥16/4μg/mL, and all 54 isolates had MBBCs >32μg/mL. Of the 54 isolates, 45 (83.3%) tested susceptible to cefepime, with the MIC50/MIC90 being 4/16μg/mL, respectively, and the MBIC90 and MBBC90 both being >256μg/mL. Although ceftolozane/tazobactam is a promising antimicrobial agent for the treatment of P. aeruginosa infections, it is not highly active against P. aeruginosa biofilms.

Original languageEnglish (US)
JournalDiagnostic Microbiology and Infectious Disease
DOIs
StateAccepted/In press - Nov 25 2015

Fingerprint

Biofilms
Pseudomonas aeruginosa
Pseudomonas Infections
Growth Plate
Microbial Sensitivity Tests
Cephalosporins
Anti-Infective Agents
tazobactam drug combination ceftolozane
In Vitro Techniques
Cations
Guidelines
Infection

Keywords

  • Biofilm
  • Ceftolozane
  • Pseudomonas aeruginosa
  • Tazobactam

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states. / Velez Perez, Antonio L.; Schmidt-Malan, Suzannah M.; Kohner, Peggy C.; Karau, Melissa J.; Greenwood-Quaintance, Kerryl E.; Patel, Robin.

In: Diagnostic Microbiology and Infectious Disease, 25.11.2015.

Research output: Contribution to journalArticle

Velez Perez, Antonio L. ; Schmidt-Malan, Suzannah M. ; Kohner, Peggy C. ; Karau, Melissa J. ; Greenwood-Quaintance, Kerryl E. ; Patel, Robin. / In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states. In: Diagnostic Microbiology and Infectious Disease. 2015.
@article{ba3d76a5a847404991e2091824f48eac,
title = "In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states",
abstract = "Pseudomonas aeruginosa causes a variety of life-threatening infections, some of which are associated with planktonic and others with biofilm states. Herein, we tested the combination of the novel cephalosporin, ceftolozane, with the β-lactamase inhibitor, tazobactam, against planktonic and biofilm forms of 54 clinical isolates of P. aeruginosa, using cefepime as a comparator. MIC values were determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum biofilm inhibitory concentration (MBIC) values were determined using biofilm-laden pegged lids incubated in antimicrobial challenge plates containing varying concentrations of ceftolozane/tazobactam. Pegged lids were then incubated in growth recovery plates containing cation-adjusted Mueller-Hinton broth to determine the minimum biofilm bactericidal concentration (MBBC). Ceftolozane/tazobactam was highly active against planktonic P. aeruginosa, with all 54 isolates studied testing susceptible (MIC ≤4/4μg/mL). On the other hand, 51/54 biofilm P. aeruginosa had MBICs ≥16/4μg/mL, and all 54 isolates had MBBCs >32μg/mL. Of the 54 isolates, 45 (83.3{\%}) tested susceptible to cefepime, with the MIC50/MIC90 being 4/16μg/mL, respectively, and the MBIC90 and MBBC90 both being >256μg/mL. Although ceftolozane/tazobactam is a promising antimicrobial agent for the treatment of P. aeruginosa infections, it is not highly active against P. aeruginosa biofilms.",
keywords = "Biofilm, Ceftolozane, Pseudomonas aeruginosa, Tazobactam",
author = "{Velez Perez}, {Antonio L.} and Schmidt-Malan, {Suzannah M.} and Kohner, {Peggy C.} and Karau, {Melissa J.} and Greenwood-Quaintance, {Kerryl E.} and Robin Patel",
year = "2015",
month = "11",
day = "25",
doi = "10.1016/j.diagmicrobio.2016.02.014",
language = "English (US)",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states

AU - Velez Perez, Antonio L.

AU - Schmidt-Malan, Suzannah M.

AU - Kohner, Peggy C.

AU - Karau, Melissa J.

AU - Greenwood-Quaintance, Kerryl E.

AU - Patel, Robin

PY - 2015/11/25

Y1 - 2015/11/25

N2 - Pseudomonas aeruginosa causes a variety of life-threatening infections, some of which are associated with planktonic and others with biofilm states. Herein, we tested the combination of the novel cephalosporin, ceftolozane, with the β-lactamase inhibitor, tazobactam, against planktonic and biofilm forms of 54 clinical isolates of P. aeruginosa, using cefepime as a comparator. MIC values were determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum biofilm inhibitory concentration (MBIC) values were determined using biofilm-laden pegged lids incubated in antimicrobial challenge plates containing varying concentrations of ceftolozane/tazobactam. Pegged lids were then incubated in growth recovery plates containing cation-adjusted Mueller-Hinton broth to determine the minimum biofilm bactericidal concentration (MBBC). Ceftolozane/tazobactam was highly active against planktonic P. aeruginosa, with all 54 isolates studied testing susceptible (MIC ≤4/4μg/mL). On the other hand, 51/54 biofilm P. aeruginosa had MBICs ≥16/4μg/mL, and all 54 isolates had MBBCs >32μg/mL. Of the 54 isolates, 45 (83.3%) tested susceptible to cefepime, with the MIC50/MIC90 being 4/16μg/mL, respectively, and the MBIC90 and MBBC90 both being >256μg/mL. Although ceftolozane/tazobactam is a promising antimicrobial agent for the treatment of P. aeruginosa infections, it is not highly active against P. aeruginosa biofilms.

AB - Pseudomonas aeruginosa causes a variety of life-threatening infections, some of which are associated with planktonic and others with biofilm states. Herein, we tested the combination of the novel cephalosporin, ceftolozane, with the β-lactamase inhibitor, tazobactam, against planktonic and biofilm forms of 54 clinical isolates of P. aeruginosa, using cefepime as a comparator. MIC values were determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum biofilm inhibitory concentration (MBIC) values were determined using biofilm-laden pegged lids incubated in antimicrobial challenge plates containing varying concentrations of ceftolozane/tazobactam. Pegged lids were then incubated in growth recovery plates containing cation-adjusted Mueller-Hinton broth to determine the minimum biofilm bactericidal concentration (MBBC). Ceftolozane/tazobactam was highly active against planktonic P. aeruginosa, with all 54 isolates studied testing susceptible (MIC ≤4/4μg/mL). On the other hand, 51/54 biofilm P. aeruginosa had MBICs ≥16/4μg/mL, and all 54 isolates had MBBCs >32μg/mL. Of the 54 isolates, 45 (83.3%) tested susceptible to cefepime, with the MIC50/MIC90 being 4/16μg/mL, respectively, and the MBIC90 and MBBC90 both being >256μg/mL. Although ceftolozane/tazobactam is a promising antimicrobial agent for the treatment of P. aeruginosa infections, it is not highly active against P. aeruginosa biofilms.

KW - Biofilm

KW - Ceftolozane

KW - Pseudomonas aeruginosa

KW - Tazobactam

UR - http://www.scopus.com/inward/record.url?scp=84964597352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964597352&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2016.02.014

DO - 10.1016/j.diagmicrobio.2016.02.014

M3 - Article

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

ER -